HANSHOW/INTERGAMMA
15.5.2024 10:01:31 CEST | Business Wire | Press release
Hanshow, a global leader in digital retail solutions, has announced its exclusive partnership with Intergamma, the market leader in the Benelux DIY sector, initiating the official installation of Hanshow's Electronic Shelf Labels (ESLs) in November 2023. This collaboration aims to deliver a unique and seamless shopping experience for customers across all channels. This collaboration signals an exciting development in the retail industry as it expands Hanshow's presence in the non-food retail sector with Intergamma operating under the prominent Gamma and Karwei brands, with nearly 400 stores in the Netherlands and Belgium. As of February 2024, installation progress includes the successful completion of ESL deployments in all 128 Karwei stores, with installations for Gamma outlets actively ongoing.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240504881462/en/
Hanshow ESLs at Intergamma. (Photo: Business Wire)
Joining forces with Hanshow and utilizing the cutting-edge electronic shelf label (ESL) solution, Intergamma will further streamline in-store operations and enhance the customer journey in its stores for certain categories. As the largest DIY online platform in the Benelux region, Intergamma is committed to breaking boundaries and offering seamless shopping from online search to in-store purchases. Hanshow's ESL solution provides real-time synchronization of product information and pricing across all channels, reducing pricing discrepancies and improving the overall in-store experience.
This partnership marks a significant milestone for both companies. Through this alliance, Intergamma will leverage Hanshow's ESL technology to provide customers with an enhanced smart shopping experience for selected categories.
The key advantages of Hanshow's ESL solutions include:
- Innovation in ESL: Hanshow is at the forefront of ESL technology, offering holistic ESL solutions specifically for the DIY industry.
- Technology Leadership: Hanshow's new generation HiLPC protocol offers retailers top-tier ESL management, rapid response times, reliable service, and precise cross-channel pricing to enhance O2O capabilities.
- Industry Expertise: Leveraging extensive experience in the DIY sector, Hanshow aids Intergamma in advancing its digital transformation efforts.
Intergamma's values of fostering a sustainable future is also aligned with the introduction of Hanshow's eco-friendly operational model.
Jurre Mulder, Chief Digital & Technology Officer at Intergamma said, “We are happy to announce our partnership with renowned supplier digital store solutions Hanshow. Through this collaboration, Intergamma demonstrates its dedication to incorporating cutting-edge technology and improving the shopping experience for its devoted customers. In the next 9 months we will roll out ESL in our stores for the paint and electrical tools departments. We're excited to raise the bar for retail innovation together.”
“This collaboration with Intergamma is an important milestone in our journey to expand into the DIY retail field,” said Liangyan Li, SVP, Head of Global Sales, Hanshow. “This partnership is a great starting point, and in the future, Intergamma and Hanshow will continue to collaborate deeply, accelerating innovation and integration, and jointly promoting the digitization and sustainable development of the DIY retail industry.”
About Intergamma
Intergamma B.V. is the market leader in the do-it-yourself market in the Benelux with its retail formulas GAMMA Netherlands, GAMMA Belgium and KARWEI. With a strong store network and cross-channel strategy, Intergamma inspires and helps its customers to turn their house and garden into a comfortable and sustainable home. Learn more: www.intergamma.nl
About Hanshow
Hanshow is a global leader in developing and manufacturing electronic shelf labels and digital store solutions. The company offers customers a series of customized IoT touchpoints and digital store solutions that deliver customer-centric insights. Hanshow's solutions have provided services to a vast number of stores in over 50 countries and regions, helping them streamline operations, optimize pricing strategies, and offer consumers a more personalized experience. Learn more: www.hanshow.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240504881462/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release
Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release
Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom